Aelis Farma SA (AELIS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aelis Farma SA (AELIS) has a cash flow conversion efficiency ratio of -0.635x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.88 Million ≈ $-4.54 Million USD) by net assets (€6.11 Million ≈ $7.15 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Aelis Farma SA (AELIS) net asset quality to measure how much of total assets are equity-financed.
Aelis Farma SA - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Aelis Farma SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Aelis Farma SA's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Aelis Farma SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aelis Farma SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Riversgold Ltd
AU:RGL
|
-19.655x |
|
Hanwha Investment&Securities Co Ltd Pref
KO:003535
|
-0.112x |
|
Modernland Realty Ltd Tbk
JK:MDLN
|
0.000x |
|
Equus Total Return Closed Fund
NYSE:EQS
|
-0.012x |
|
Kumpulan H & L High-Tech Bhd
KLSE:7033
|
0.035x |
|
Marpai Inc
NASDAQ:MRAI
|
0.014x |
|
Capital Point
TA:CPTP
|
-0.017x |
|
Raspberry Pi Holdings PLC
LSE:RPI
|
0.028x |
Annual Cash Flow Conversion Efficiency for Aelis Farma SA (2018–2024)
The table below shows the annual cash flow conversion efficiency of Aelis Farma SA from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see AELIS market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €10.12 Million ≈ $11.83 Million |
€-11.83 Million ≈ $-13.83 Million |
-1.170x | -22.67% |
| 2023-12-31 | €13.20 Million ≈ $15.43 Million |
€-12.59 Million ≈ $-14.71 Million |
-0.953x | -44.57% |
| 2022-12-31 | €19.79 Million ≈ $23.14 Million |
€-13.05 Million ≈ $-15.26 Million |
-0.659x | -103.12% |
| 2021-12-31 | €898.00K ≈ $1.05 Million |
€18.97 Million ≈ $22.18 Million |
21.125x | +505.27% |
| 2020-12-31 | €-710.00K ≈ $-830.06K |
€-2.48 Million ≈ $-2.90 Million |
3.490x | +245.50% |
| 2019-12-31 | €1.20 Million ≈ $1.41 Million |
€-2.89 Million ≈ $-3.38 Million |
-2.399x | -61.24% |
| 2018-12-31 | €2.38 Million ≈ $2.79 Million |
€-3.55 Million ≈ $-4.15 Million |
-1.488x | -- |
About Aelis Farma SA
Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; an… Read more